Pasithea Therapeutics (KTTA) Return on Sales (2022)

Pasithea Therapeutics recorded quarterly Return on Sales of 0.04% in Q4 2022, down 144.64% quarter-over-quarter from 0.02% in Q3 2022.

Pasithea Therapeutics' Return on Sales history runs 1 years deep, the most recent figure standing at 0.04% for Q4 2022.

  • In Q4 2022, Return on Sales changed N/A year-over-year to 0.04%; the TTM figure through Dec 2022 stood at 0.05% (changed N/A YoY), while the FY2022 annual figure was 0.05%, up 140.0% from the prior year.
  • Return on Sales came in at 0.04% for Q4 2022 at Pasithea Therapeutics, down from 0.02% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.02% in Q3 2022 to a low of 0.34% in Q2 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn 0.00%
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn 0.00%
7 Evaxion A 64.16 Bn 64.14 Bn - 0.00%
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn 0.00%
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn 0.00%
10 Pasithea Therapeutics 17.41 Mn 17.41 Mn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2022 -0.04%
Sep 30, 2022 -0.02%
Jun 30, 2022 -0.34%
Mar 31, 2022 -0.24%